On December 8, 2017 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported new results from two studies with EndoPredict are being featured at the 2017 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas (Press release, Myriad Genetics, DEC 8, 2017, View Source [SID1234522466]). EndoPredict is a second-generation prognostic gene expression test for patients with breast cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to present new data on our EndoPredict test which demonstrates our ongoing commitment to collaborate with leading academic research centers and advance personalized medicine for patients with breast cancer," said Ralf Kronenwett, M.D., Ph.D., director of International Medical Affairs, Myriad Genetics. "Importantly, these new studies add to the expanding body of evidence demonstrating how EndoPredict can be used to predict both disease recurrence as well as response to therapy."
The data are highlighted below and abstracts are available at: View Source Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #SABCS17.

EndoPredict Podium Presentation
Title: The EndoPredict score predicts residual cancer burden to neoadjuvant chemotherapy and to neuroendocrine therapy in HR+/HER2- breast cancer patients from ABCSG34.
Presenter: Peter Dubsky, M.D., Medical University of Vienna, Austria and the Breast Center St. Anna Klinik, Lucerne.
Date: Friday, Dec. 8, 2017, 3:15—5:00 p.m.
Location: Podium, GS6-04

This study was designed to show the predictive value of the EndoPredict (EP) 12-gene molecular score for tumor response to neoadjuvant chemotherapy and neoendocrine therapy. The study included biopsies from 217 women with HR+ breast cancer. Of these, 134 patients were assigned to receive neoadjuvant chemotherapy according to aggressive clinico-pathologic tumor features. The remaining 83 patients were clinically identified as having luminal A types of breast cancer and were assigned to receive neoendocrine treatment. The primary endpoint was residual cancer burden RCB0/I (i.e., good tumor response) vs. RCB II/III (i.e., poor tumor response) at time of surgery.
In the neoadjuvant chemotherapy group, 125 patients had high EP scores and nine had a low EP score. The results show that 26.4 percent of those with a high score showed a good tumor response (RCB0/I) to neoadjuvant chemotherapy, while all patients with a low score showed only a poor tumor response (Table 1). In the "luminal A" group receiving neoendocrine therapy, 39 patients had a high EP score and 44 had a low EP score. The results show that 27.3 percent of those with a low EndoPredict score and 7.7 percent with a high score achieved excellent tumor response (RCB0/I) to neoendocrine therapy (Table 1).

Table. 1 EndoPredict
Low Score EndoPredict
High Score
p-Value
Response to
Neoadjuvant
Chemotherapy 0.0 % 26.4 % p=0.0001
Response to
Endocrine Therapy 27.3 % 7.7 % P=0.015

"This exciting study is evidence that women with a high EP score responded better to neoadjuvant chemotherapy than those with a low score, while those with a low EndoPredict score responded better to neoadjuvant endocrine therapy," said Peter Dubsky, M.D., principal investigator, speaking on behalf of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). "These findings are relevant to better patient selection for biomarker driven studies in the neoadjuvant setting."

EndoPredict Poster Presentation
Title: The role of EndoPredict in invasive lobular carcinoma.
Presenter: Ivana Sestak, Ph.D., Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London.
Date: Thursday, Dec. 7, 2017, 5:00—7:00 p.m.
Location: Poster, P3-08-01

This study evaluated the role of EndoPredict molecular-clinical score (EPclin) for the prediction of distant recurrence in women diagnosed with invasive lobular carcinoma (ILC) compared to those with invasive ductal carcinoma (IDC). The study included 928 women with E R+/HER2- breast cancer: 141 had ILC, 710 had IDC and 77 were mixed type.
This result shows that EndoPredict provided significant power for predicting distant recurrence in patients with both ILC (EPclin: LR-X2=5.8) and IDC (EPclin: LR-X2=13.8). Women with ILC who had a high EPclin score were at seven times increased risk of 10-year distant recurrence with endocrine therapy only than patients with low EPclin score. In comparison, women with IDC who had a high EPclin score were at five times increased risk of 10-year recurrence than patients with low EPclin score. Importantly, there was a similar 10-year distant recurrence risk in patients with a low EPclin score (~6 percent), which suggests that chemotherapy is not indicated in these patients with a low risk score regardless of tumor type.
"Our results show that EndoPredict provided highly significant prognostic information and risk stratification in women with invasive lobular carcinoma," said Ivana Sestak, Ph.D., principal investigator, Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London. "Importantly, the 10-year risk of distant recurrence in the EndoPredict low-risk groups was similar between ILC and IDC, suggesting that chemotherapy is not indicated for these patients, irrespective of tumor type."

About EndoPredict
EndoPredict is a second-generation, multigene prognostic test for patients diagnosed with breast cancer. The test provides physicians with information to devise personalized treatment plans for their patients. EndoPredict has been validated in approximately 4,000 patients with node-negative and node-positive cancer and has been used clinically in more than 20,000 patients. In contrast to first-generation multigene prognostic tests, EndoPredict detects the likelihood of late metastases (i.e., metastasis formation after more than five years) and, therefore, can guide treatment decisions regarding the need for chemotherapy, as well as extended anti-hormonal therapy. Accordingly, therapy decisions backed by EndoPredict confer a high level of diagnostic safety. For more information, please visit: www.endopredict.com.

On December 8, 217 Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, reported that the first subject has been treated in the APOLLO study of FATE-NK100 in women with ovarian cancer resistant to, or recurrent on, platinum-based treatment (Press release, Fate Therapeutics, DEC 8, 2017, View Source [SID1234522461]). The clinical trial is intended to evaluate the safety and determine the maximum dose of FATE-NK100, the Company’s first-in-class, donor-derived adaptive memory natural killer (NK) cell cancer therapy, as a monotherapy when administered intraperitoneally in the outpatient setting. A clinical assessment of patients with ovarian cancer has previously shown that endogenous NK cells within the peritoneal fluid exhibit an altered phenotype with reduced cytolytic function.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Women today often are treated with intraperitoneal chemotherapy, and the administration of FATE-NK100 directly within the peritoneal cavity is an exciting therapeutic strategy to restore NK cell function, promote persistence and inhibit tumor growth," said Melissa A. Geller, M.D., Associate Professor in the Department of Obstetrics, Gynecology and Women’s Health, Division of Gynecologic Oncology at the University of Minnesota and the lead investigator of the clinical trial at the Masonic Cancer Center. "Ovarian cancer is a disease of middle age women, and over 60% of women with ovarian cancer initially present with advanced disease. For these women, the rate of recurrence is around 70%, and there is an urgent need for novel therapeutic strategies since standard treatments in the recurrent setting provide dismal response rates especially in platinum resistant disease."

The APOLLO study is an open-label, accelerated dose-escalation, Phase 1 clinical trial of FATE-NK100 in subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer. Up to three dose levels of FATE-NK100 are intended to be assessed to evaluate safety and determine the maximum dose. Other endpoints to be evaluated include objective response rate at 28 days, and progression-free and overall survival at six months. Subjects with stable disease or better at Day 28 following infusion may be considered for retreatment with FATE-NK100.

Ovarian cancer is the fifth leading cause of cancer-related death among women, and is the deadliest of gynecologic cancers. The American Cancer Society estimates that in 2017, about 22,440 new cases of ovarian cancer will be diagnosed and 14,080 women will die of ovarian cancer in the United States. While a high proportion of women respond to initial platinum-based chemotherapy, around 70% of patients diagnosed with ovarian cancer will have a recurrence. While recurrent ovarian cancer is treatable, it is rarely curable and there is a significant need for more effective, better-tolerated therapies.

About FATE-NK100
FATE-NK100 is a first-in-class, donor-derived natural killer (NK) cell cancer immunotherapy comprised of adaptive memory NK cells, a highly specialized and functionally distinct subset of activated NK cells expressing the maturation marker CD57. Higher frequencies of CD57+ NK cells in the peripheral blood or tumor microenvironment in cancer patients have been linked to better clinical outcomes. In preclinical studies, FATE-NK100 has demonstrated enhanced anti-tumor activity across a broad range of hematologic and solid tumors, with augmented cytokine production, improved persistence and increased resistance to immune checkpoint pathways compared to other NK cell therapies that are being clinically administered today. FATE-NK100 is produced through a feeder-free, seven-day manufacturing process during which NK cells sourced from a healthy donor are activated ex vivo with pharmacologic modulators.

About APOLLO
APOLLO is an open-label, accelerated dose-escalation, Phase 1 clinical trial in subjects with recurrent ovarian, fallopian tube or primary peritoneal cancer designed to evaluate the safety and determine the maximum dose of a single infusion of FATE-NK100 as a monotherapy when administered via intraperitoneal catheter after out-patient chemotherapy followed by sub-cutaneous IL-2 administration. Up to three dose levels of FATE-NK100 are intended to be assessed (1×107 cells/kg, >1×107 cells/kg to ≤3×107 cells/kg, and up to 1×108 cells/kg). In the event a dose limiting toxicity is observed, the clinical trial will convert to a 3+3 design. A ten-subject expansion cohort is expected to be enrolled at the maximum dose level. Other endpoints include objective response rate at 28 days, and progression-free and overall survival at six months, post-infusion of FATE-NK100. The clinical trial is being conducted at the Masonic Cancer Center, University of Minnesota as an investigator-initiated study.

On December 8, 2017 Adaptive Biotechnologies, the leader in using next-generation sequencing (NGS) to detect minimal/measurable residual disease (MRD) in blood cancers, and its collaborators reported that they will present 22 studies, including a late-breaker presentation, at the 59th Annual Meeting of the American Society of Hematology (ASH) (Free ASH Whitepaper) in Atlanta, December 9-12 (Press release, , DEC 8, 2017, View Source [SID1234522517]). Data presented at ASH (Free ASH Whitepaper) will demonstrate how Adaptive’s clonoSEQ Assay to measure MRD, the cancerous cells remaining in the body after treatment, can inform clinical care in patients with B and T cell lymphoid malignancies. Additionally, at ASH (Free ASH Whitepaper), Adaptive and its collaborators will present data from studies utilizing the company’s research-based immunosequencing platform, immunoSEQ, to identify potential biomarkers of response to therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"MRD is increasingly viewed as a critical endpoint in lymphoid cancers used to assess a patient’s response to cancer treatment and evaluate disease burden over time. At Adaptive, we are excited to see the growing use of this endpoint to support clinical trials and patient management," said Charles Sang, Senior Vice President of Diagnostics. "We leveraged our foundational immunosequencing platform to develop the clonoSEQ Assay which provides a highly sensitive and standardized determination of residual disease in patients with lymphoid malignancies."

clonoSEQ, the first clinical application of Adaptive’s pioneering immunosequencing platform, is helping to set a new standard for assessment of minimal residual disease in the clinic. It will be featured in a late breaker presentation, 5 orals and 7 posters. Data will be presented across a range of cancers – 9 multiple myeloma, 1 peripheral T-cell lymphoma, 1 mantle cell lymphoma, 1 chronic lymphocytic leukemia, 1 follicular lymphoma. Abstracts of importance include:

LBA-4 Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE) (LBA-4)
Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial (Abstract #435)
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux (Abstract #739)
Below is a full list of clonoSEQ and immunoSEQ related abstracts that will be presented at ASH (Free ASH Whitepaper) this year.

CLONOSEQ ORAL ABSTRACT AND POSTER PRESENTATION HIGHLIGHTS:

Saturday, December 9, 2017

Oral Presentation, Abstract #154 Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Presenter: Jia Ruan, MD, PhD, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY

Time: 12:45 – 1:00 PM

Location: Bldg A, Lvl 4, A411-A412 (Georgia World Congress Center)

Poster Presentation, Abstract #1824 Daratumumab in Combination with Pomalidomide and Dexamethasone for RRMM Patients with ≥2 Prior Lines of Therapy: Updated Analysis of MMY1001

Presenter: Thierry Facon, Department of Haematology, Lille University Hospital, Lille, France

Time: 5:30 – 7:30 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Poster Presentation, Abstract #1852 Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Presenter: Suzanne Lentzsch, Columbia University Medical Center, New York, NY

Time: 5:30 – 7:30 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Poster Presentation, Abstract #1883 Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in RRMM Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of Pollux

Presenter: Philippe Moreau, Hematology, University Hospital Hôtel-Dieu, Nantes, France

Time: 5:30 – 7:30 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Sunday, December 10, 2017

Oral Presentation, Abstract #435 Minimal Residual Disease in Multiple Myeloma: Final Analysis of the IFM2009 Trial

Presenter: Hervé Avet-Loiseau, MD, PhD, UC-Oncopole, Unite de Genomique du Myelome, Toulouse, France

Time: 12:30 – 12:45 PM

Location: Bldg C, Lvl 1, Hall C4 (Georgia World Congress Center)

Oral Presentation, Abstract #496 A Multicenter, Phase II Study of Ibrutinib Plus FCR As Frontline Therapy for Younger CLL Patients

Presenter: Matthew S. Davids, MD, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA

Time: 5:15 – 5:30 PM

Location: Bldg B, Lvl 5, Murphy BR 3-4 (Georgia World Congress Center)

Poster Presentation, Abstract #2728 Next-Generation Sequencing Based Monitoring of Circulating-Tumor DNA in Untreated Peripheral T-Cell Lymphoma

Presenter: Christopher Melani, MD, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Baltimore, MD

Time: 6:00 – 8:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Poster Presentation, Abstract #3145 Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in RRMM: Updated Efficacy and Safety Analysis of Castor

Presenter: Andrew Spencer, MD, Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia

Time: 6:00 – 8:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Monday, December 11, 2017

Oral Presentation, Abstract #739 Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux

Presenter: Meletios A. Dimopoulos, National and Kapodistrian University of Athens, Athens, Greece

Time: 2:45 – 3:00 PM

Location: Bldg C, Lvl 1, Hall C1 (Georgia World Congress Center)

Poster Presentation, Abstract #4533 High Rate of Sustained Minimal Residual Disease Negativity Predicts Prolonged Survival for the Overall Patient Population in the Phase 2 KRd Plus Autologous Stem Cell Transplantation MMRC Trial

Presenter: Andrzej J. Jakubowiak, MD, University of Chicago Medical Center, Chicago, IL

Time: 6:00 – 8:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Poster Presentation, Abstract #4685 Measurable Residual Disease (MRD) Testing in Multiple Myeloma Using an Improved Testing Technology: Population Impact

Presenter: Marita Zimmermann, PhD, MPH, Veritech Corporation, Seattle, WA

Time: 6:00 – 8:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Tuesday, December 12, 2017

Late Breaker Presentation: LBA-4 Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible for Transplant (ALCYONE)

Presenter: Maria-Victoria Mateos, University Hospital of Salamanca/IBSAL, Salamanca, Spain

Time: 7:30 AM-9:00 AM

Location: Bldg C, Lvl 1, Hall C2-C3 (Georgia World Congress Center)

IMMUNOSEQ ABSTRACT AND POSTER PRESENTATION HIGHLIGHTS:

Saturday, December 9, 2017

Poster Presentation, Abstract #1898 Quantifying the Size and Diversity of the Human Alloresponse Via High-Throughput T Cell Receptor Sequencing

Presenter: Susan DeWolf, MD, Columbia Center for Translational Immunology (CCTI), Columbia University Medical Center, New York, NY

Time: 5:30 – 7:30 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Poster Presentation, Abstract #2069 Novel Human Anti-HLA-Bw4 and B61 Monoclonal Antibodies Kill Malignant B Cells Via CDC/ADCC While Sparing Normal Peripheral Blood Cells

Presenter: Hiroyuki Takamatsu, MD, PhD, Department of Hematology, Kanazawa University, Kanazawa, Japan

Time: 5:30 – 7:30 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Sunday, December 10, 2017

Poster Presentation, Abstract #2454 Surveillance of the Immune Repertoire of Aplastic Anemia Patients Using Deep Sequencing

Presenter: Cassandra Hirsch, BS, Department of Translational Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Time: 6:00 – 8:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Poster Presentation, Abstract #2734 Longitudinal Analyses of the Genomic, Transcriptomic, and T-Cell Repertoire in Diffuse Large B-Cell Lymphoma Demonstrates Changes in Signaling and Immune Recognition at Relapse

Presenter: Shamzah Araf, MRCP, MBBS, Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Time: 6:00 – 8:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Poster Presentation, Abstract #2771 Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab

Presenter: Christopher Flowers, MD, MS, Winship Cancer Institute Bone Marrow & Stem Cell Transplantation, Atlanta, GA

Time: 6:00 – 8:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Monday, December 11, 2017

Oral Presentation, Abstract #649 Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

Presenter: Alex F. Herrera, MD, City of Hope, Duarte, CA

Time: 10:30 – 10:45 AM

Location: Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center)

Oral Presentation, Abstract #728 The Tumor Microenvironment Is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma

Presenter: Joshua W.D. Tobin, University of Queensland, Australia

Time: 3:00 – 3:15 PM

Location: Bldg C, Lvl1, C101 Auditorium (Georgia World Congress Center)

Oral Presentation, Abstract #825 The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial

Presenter: Mohamed Shanavas, MD, University of Queensland Diamantina Institute, Brisbane, Australia

Time: 5:00 PM

Location: Bldg C, Lvl 3, Georgia BR 1-3 (Georgia World Congress Center)

Poster Presentation, Abstract # 4506 Day 90 Post-Allogeneic Hematopoietic Cell Transplantation T Cell Receptor Diversity Level Correlates with Risk of Relapse in Patients with Multiple Myeloma

Presenter: Robert Korngold, PhD, John Theurer Cancer Center, Hackensack Univ. Med. Ctr. Jurist Research Bldg., Hackensack, NJ

Time: 6:00 – 8:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

About Minimal/Measurable Residual Disease

Minimal/measurable residual disease (MRD) in hematologic malignancies refers to cancer cells that remain in the body of a person with cancer after treatment. In the case of clonoSEQ this includes ALL and MM. These cells can be present at levels undetectable by traditional morphologic, microscopic examination of blood, bone marrow or a lymph node biopsy. Sensitive molecular technologies, such as next-generation sequencing utilized by the Adaptive Biotechnologies clonoSEQ Assay, may be employed to facilitate the reliable detection of MRD at levels below the limits of traditional assessment.

About the clonoSEQ Assay

The Adaptive Biotechnologies clonoSEQ Assay enables physicians to utilize a molecular, next-generation sequencing-based minimal/measurable residual disease (MRD) detection method. The clonoSEQ Assay detects and quantifies DNA sequences found in malignant cells which can be tracked throughout treatment. This robust assay provides consistent, accurate measurement of disease burden which potentially allows physicians to visualize response to treatment over time. The clonoSEQ assay is not approved or cleared by the FDA and is currently available in a CLIA-certified laboratory. clonoSEQ test results should only be used taking into account all available clinical information and should not be used as the sole determinant of patient care and management.

About the immunoSEQ Platform

Adaptive’s immunoSEQ Platform helps researchers make discoveries in areas such as oncology, autoimmune disorders, infectious diseases and basic immunology. The immunoSEQ Assays can identify millions of T- and B-cell receptors from a single sample in exquisite detail. Offered as a Service or Kit, immunoSEQ Assays provide quantitative, reproducible sequencing results along with access to powerful, easy-to-use analysis tools. The immunoSEQ Assays are for research use only and are not for use in diagnostic procedures.

On December 8, 2017 Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) reported that the company is scheduled to present at the 2017 BMO Capital Markets Prescriptions for Success Healthcare Conference at 11:30 AM ET on Thursday, December 14, 2017 in New York City (Press release, Pacira Pharmaceuticals, DEC 8, 2017, View Source;p=RssLanding&cat=news&id=2321829 [SID1234522467]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the Pacira presentation can be accessed by visiting the "Investors & Media" section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.

On December 8, 2017 TG Therapeutics, Inc. (NASDAQ:TGTX), reported the schedule of data presentations for the Company’s lead compounds, TGR-1202, (umbralisib), the Company’s once-daily PI3K delta inhibitor, and TG-1101 (ublituximab), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, at the upcoming 59th American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting, being held December 9-12, 2017, at the Georgia World Congress Center in Atlanta, Georgia (Press release, TG Therapeutics, DEC 8, 2017, View Source [SID1234522474]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster presentations at the ASH (Free ASH Whitepaper) 2017 meeting include the following:

Sunday December 10, 2017:

Title: Phase I/II Study of Pembrolizumab in Combination with Ublituximab (TG-1101) and Umbralisib (TGR-1202) in Patients with Relapsed/Refractory CLL
• Abstract Number: 3010
• Session: 642. CLL: Therapy, excluding Transplantation: Poster II
• Date and Time: Sunday, December 10, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Anthony R. Mato, MD, University of Pennsylvania, Philadelphia, PA

Title: Umbralisib/TGR-1202 as a Novel Dual PI3K/CK1 Inhibitor Has a Unique Therapeutic Role in Silencing Oncogenes in Aggressive Lymphomas
• Abstract Number: 2809
• Session: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Poster II
• Date and Time: Sunday, December 10, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Ipsita Pal, PhD, Columbia University Medical Center, New York, NY

Title: Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine Model
• Abstract Number: 3009
• Session: 642. CLL: Therapy, excluding Transplantation: Poster II
• Date and Time: Sunday, December 10, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Kamira K. Maharaj, BS, Moffit Cancer Center, Tampa, FL
Monday, December 11, 2017:

Title: An Integrated Safety Analysis of the Next Generation PI3Kδ Inhibitor Umbralisib (TGR-1202) in Patients with Relapsed/Refractory Lymphoid Malignancies
• Abstract Number: 4037
• Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
• Date and Time: Monday, December 11, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Matthew S. Davids, MD, Dana Farber Cancer Institute, Boston, MA

Title: KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-δ Inhibitor Therapy
• Abstract Number: 4314
• Session: 642. CLL: Therapy, excluding Transplantation: Poster III
• Date and Time: Monday, December 11, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Anthony R. Mato, MD, University of Pennsylvania, Philadelphia, PA

Title: PI3K-Delta Inhibitors Induce Primary Monocyte Cytotoxicity but Do Not Alter Monocyte Differentiation
• Abstract Number: 4284
• Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster III
• Date and Time: Monday, December 11, 2017; 6:00 PM – 8:00 PM ET
• Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
• Presenter: Daphne Friedman, MD, Durham VA/Duke University Medical Center, Durham, NC
The above referenced abstracts can be viewed online through the ASH (Free ASH Whitepaper) meeting website at www.hematology.org. Following each presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com.

TG THERAPEUTICS INVESTOR & ANALYST EVENT

TG Therapeutics will also host a reception on Sunday, December 10, 2017 beginning at 8:00pm ET with featured presentations beginning promptly at 8:15pm ET. The event will take place at the Ritz Carlton Atlanta (Downtown) in the Salon I/II Room on the lower level. This event will be webcast live and will be available on the Events page, located within the Investors & Media section of the Company’s website at www.tgtherapeutics.com, as well as archived for future review. This event will also be broadcast via conference call. To access the conference line, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), and reference Conference Title: TG Therapeutics December 2017 Investor & Analyst Event.